iRhythm Technologies provides diagnostic monitoring solutions that facilitate the early diagnosis and treatment of cardiac arrhythmia.
iRhythm provides innovative and cost-effective diagnostic monitoring solutions that facilitate early diagnosis and treatment decisions, with the goal of ultimately improving patient health outcomes and reducing wasteful healthcare spending. Its flagship product, the Zio® Patch, is designed to optimize and simplify the diagnosis of cardiac arrhythmias. Zio® Patch is the smallest, lightest, least conspicuous cardiac arrhythmia diagnostic available and is indicated for up to 14-day monitoring.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 21, 2020 | Post-IPO Secondary | $220M | — | — | — | Detail |
Sep 11, 2019 | Post-IPO Equity | $115M | — | — | — | Detail |
Oct 20, 2016 | IPO | $107M | — | — | — | Detail |
May 22, 2014 | Series E | $27.34M | 2 |
![]() |
— | Detail |
Apr 10, 2013 | Series D | $16M | 5 |
![]() |
— | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Oct 10, 2019
![]() |
Series B | $26M | Health Care | — |
Apr 21, 2016
![]() |
Seed | — | Health Care | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Series E |
![]() |
Yes | Series Unknown |
![]() |
— | Series E |
|
— | Series D |
![]() |
— | Series D |
![]() |
— | Series D |
![]() |
— | Series D |
![]() |
— | Private Equity(PE) |
![]() |
— | Series Unknown |
![]() |
— | Series A |